NCT05343819View on ClinicalTrials.gov

Ascending Multiple Intravenous Doses of AON-D21 in Healthy Male Subjects.

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

April 12, 2022

Primary Completion Date

November 29, 2022

Study Completion Date

November 29, 2022

Conditions
Healthy
Interventions
DRUG

AON-D21

AON-D21 is a PEGylated L-configured aptamer that binds and thereby neutralizes the complement component C5a from activating both C5a receptors.

DRUG

Placebo

Isotonic glucose solution identical in appearance to AON-D21.

Trial Locations (1)

89231

Nuvisan GmbH, Neu-Ulm

Sponsors
All Listed Sponsors
lead

Aptarion Biotech AG

INDUSTRY